BeyondBio
Latest round
- Series B
Last raised
- Aug 2016
Total raised
- $7.4M
Investors
- 4
About BeyondBio
Based in Daejeon, South Korea, and founded in 2013, BeyondBio Inc. operates as a biopharmaceutical firm that develops new low-molecular substances and uses them to develop innovative new drugs that target treatments for diseases such as Alzheimer's disease, brain tumor, pancreatic cancer, bladder cancer, and colorectal cancer. In 2015, the company entered the preclinical trial of the anticancer drug BEY1107 and completed it in 2016. BeyondBio Inc. registered a domestic substance patent and entered the preclinical trial of the Alzheimer's disease treatment BEY2153 in 2017. In May 2026, BeyondBio Inc. The company develops five pipelines, including treatment for pancreatic cancer, glioblastoma, lung cancer, and Alzheimer's disease. The company's flagship pancreatic cancer treatment product is BEY1107P, an anticancer drug that selectively acts on CDK1 among cyclin-dependent kinases or CDKs that act in cell cycle regulation. Other products are BEY1107G, a glioblastoma treatment, BEY4101 which is a treatment for lung cancer, and the Alzheimer's disease treatments BEY2153 and BEY4101A.
Who invested in BeyondBio
4 investors across 2 rounds
See all investors in BeyondBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BeyondBio
Who invested in BeyondBio?
BeyondBio has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BeyondBio raised?
BeyondBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BeyondBio last raise money?
BeyondBio's most recent round on record is a Series B, in Aug 2016.
What does BeyondBio do?
Based in Daejeon, South Korea, and founded in 2013, BeyondBio Inc.
Where is BeyondBio headquartered?
BeyondBio is headquartered in Daejeon, South Korea.
Which VCs invest in companies like BeyondBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at BeyondBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like BeyondBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.